GAMMA Investing LLC boosted its position in Mesoblast Limited (NASDAQ:MESO - Free Report) by 1,174.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 85,513 shares of the company's stock after buying an additional 78,802 shares during the quarter. GAMMA Investing LLC owned 0.07% of Mesoblast worth $1,067,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its holdings in Mesoblast by 1,503.3% in the 4th quarter. Bank of America Corp DE now owns 290,728 shares of the company's stock worth $5,756,000 after buying an additional 272,595 shares in the last quarter. Oaktree Capital Management LP acquired a new position in Mesoblast in the 4th quarter worth $3,556,000. Strategic Financial Concepts LLC acquired a new position in Mesoblast in the 4th quarter worth $2,744,000. Prosperity Wealth Management Inc. lifted its holdings in Mesoblast by 2.0% in the 4th quarter. Prosperity Wealth Management Inc. now owns 93,245 shares of the company's stock worth $1,846,000 after buying an additional 1,795 shares in the last quarter. Finally, Oaktree Fund Advisors LLC acquired a new stake in shares of Mesoblast in the 4th quarter valued at about $949,000. Institutional investors and hedge funds own 1.43% of the company's stock.
Mesoblast Stock Performance
Shares of Mesoblast stock opened at $11.78 on Monday. The firm's 50-day simple moving average is $11.22 and its 200-day simple moving average is $14.05. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. Mesoblast Limited has a 1 year low of $5.78 and a 1 year high of $22.00.
Analyst Upgrades and Downgrades
Separately, Cantor Fitzgerald upgraded shares of Mesoblast to a "strong-buy" rating in a research note on Monday, March 31st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $18.00.
View Our Latest Stock Report on MESO
Mesoblast Profile
(
Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
